SEARCH

SEARCH BY CITATION

References

  • Ahmad M., Takino T., Miyamori H., Yoshizaki T., Furukawa M. and Sato H. (2006) Cleavage of amyloid-beta precursor protein (APP) by membrane-type matrix metalloproteinases. J. Biochem. 139, 517526.
  • Allinson T. M., Parkin E. T., Condon T. P., Schwager S. L., Sturrock E. D., Turner A. J. and Hooper N. M. (2004) The role of ADAM10 and ADAM17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein. Eur. J. Biochem. 271, 25392547.
  • Amour A., Knight C. G., English W. R., Webster A., Slocombe P. M., Knauper V., Docherty A. J., Becherer J. D., Blobel C. P. and Murphy G. (2002) The enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPs. FEBS Lett. 524, 154158.
  • Anders A., Gilbert S., Garten W., Postina R. and Fahrenholz F. (2001) Regulation of the alpha-secretase ADAM10 by its prodomain and proprotein convertases. FASEB J. 15, 18371839.
  • Asai M., Hattori C., Szabo B., Sasagawa N., Maruyama K., Tanuma S. and Ishiura S. (2003) Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase. Biochem. Biophys. Res. Commun. 301, 231235.
  • Backstrom J. R., Lim G. P., Cullen M. J. and Tokes Z. A. (1996) Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1–40). J. Neurosci. 16, 79107919.
  • Bandyopadhyay S., Goldstein L. E., Lahiri D. K. and Rogers J. T. (2007) Role of the APP non-amyloidogenic signaling pathway and targeting alpha-secretase as an alternative drug target for treatment of Alzheimer’s disease. Curr. Med. Chem. 14, 28482864.
  • Bozkulak E. C. and Weinmaster G. (2009) Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. Mol. Cell. Biol. 29, 56795695.
  • Buxbaum J. D., Liu K. N., Luo Y., Slack J. L., Stocking K. L., Peschon J. J., Johnson R. S., Castner B. J., Cerretti D. P. and Black R. A. (1998) Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J. Biol. Chem. 273, 2776527767.
  • Caccamo A., Oddo S., Billings L. M., Green K. N., Martinez-Coria H., Fisher A. and LaFerla F. M. (2006) M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 49, 671682.
  • Camden J. M., Schrader A. M., Camden R. E., Gonzalez F. A., Erb L., Seye C. I. and Weisman G. A. (2005) P2Y2 nucleotide receptors enhance alpha-secretase-dependent amyloid precursor protein processing. J. Biol. Chem. 280, 1869618702.
  • Cao X. and Sudhof T. C. (2001) A transcriptively active complex of app with fe65 and histone acetyltransferase tip60. Science 293, 115120.
  • Cao X. and Sudhof T. C. (2004) Dissection of amyloid-beta precursor protein-dependent transcriptional transactivation. J. Biol. Chem. 279, 2460124611.
  • Clement A. B., Hanstein R., Schroder A., Nagel H., Endres K., Fahrenholz F. and Behl C. (2008) Effects of neuron-specific ADAM10 modulation in an in vivo model of acute excitotoxic stress. Neuroscience 152, 459468.
  • Colciaghi F., Borroni B., Pastorino L., Marcello E., Zimmermann M., Cattabeni F., Padovani A. and Di Luca M. (2002) [alpha]-Secretase ADAM10 as well as [alpha]APPs is reduced in platelets and CSF of Alzheimer disease patients. Mol. Med. 8, 6774.
  • Cole S. L. and Vassar R. (2008) BACE1 structure and function in health and Alzheimer’s disease. Curr. Alzheimer Res. 5, 100120.
  • Davis A. A., Fritz J. J., Wess J., Lah J. J. and Levey A. I. (2010) Deletion of M1 muscarinic acetylcholine receptors increases amyloid pathology in vitro and in vivo. J. Neurosci. 30, 41904196.
  • Donmez G. and Guarente L. (2010) Aging and disease: connections to sirtuins. Aging Cell 9, 285290.
  • Donmez G., Wang D., Cohen D. E. and Guarente L. (2010) SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell 142, 320332.
  • Dulin F., Leveille F., Ortega J. B., Mornon J. P., Buisson A., Callebaut I. and Colloc’h N. (2008) P3 peptide, a truncated form of A beta devoid of synaptotoxic effect, does not assemble into soluble oligomers. FEBS Lett. 582, 18651870.
  • Edwards D. R., Handsley M. M. and Pennington C. J. (2008) The ADAM metalloproteinases. Mol. Aspects Med. 29, 258289.
  • Endres K. and Fahrenholz F. (2010) Upregulation of the alpha-secretase ADAM10 - risk or reason for hope? FEBS J. 277, 15851596.
  • Esch F. S., Keim P. S., Beattie E. C., Blacher R. W., Culwell A. R., Oltersdorf T., McClure D. and Ward P. J. (1990) Cleavage of amyloid b peptide during constitutive processing of its precursor. Science 248, 11221124.
  • Escrevente C., Morais V. A., Keller S., Soares C. M., Altevogt P. and Costa J. (2008) Functional role of N-glycosylation from ADAM10 in processing, localization and activity of the enzyme. Biochim. Biophys. Acta 1780, 905913.
  • Fahrenholz F. (2007) Alpha-secretase as a therapeutic target. Curr. Alzheimer Res. 4, 412417.
  • Fellgiebel A., Kojro E., Muller M. J., Scheurich A., Schmidt L. G. and Fahrenholz F. (2009) CSF APPs alpha and phosphorylated tau protein levels in mild cognitive impairment and dementia of Alzheimer’s type. J. Geriatr. Psychiatry Neurol. 22, 39.
  • Freese C., Garratt A. N., Fahrenholz F. and Endres K. (2009) The effects of alpha-secretase ADAM10 on the proteolysis of neuregulin-1. FEBS J. 276, 15681580.
  • Furukawa K., Sopher B. L., Rydel R. E., Begley J. G., Pham D. G., Martin G. M., Fox M. and Mattson M. P. (1996) Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J. Neurochem. 67, 18821896.
  • Gibb D. R., El Shikh M., Kang D. J. et al. (2010) ADAM10 is essential for Notch2-dependent marginal zone B cell development and CD23 cleavage in vivo. J. Exp. Med. 207, 623635.
  • Grbovic O. M., Mathews P. M., Jiang Y., Schmidt S. D., Dinakar R., Summers-Terio N. B., Ceresa B. P., Nixon R. A. and Cataldo A. M. (2003) Rab5-stimulated up-regulation of the endocytic pathway increases intracellular beta-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Abeta production. J. Biol. Chem. 278, 3126131268.
  • Haass C. and Selkoe D. J. (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid beta-peptide. Nat. Rev. 8, 101112.
  • Haass C., Lemere C. A., Capell A., Citron M., Seubert P., Schenk D., Lannfelt L. and Selkoe D. J. (1995) The Swedish mutation causes early-onset Alzheimer’s disease by beta-secretase cleavage within the secretory pathway. Nat. Med. 1, 12911296.
  • Hardy J. and Selkoe D. J. (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297, 353356.
  • Hartmann D., De Strooper B., Serneels L. et al. (2002) The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum. Mol. Genet. 11, 26152624.
  • Hattori M., Osterfield M. and Flanagan J. G. (2000) Regulated cleavage of a contact-mediated axon repellent. Science 289, 13601365.
  • Hebert S. S., Serneels L., Tolia A., Craessaerts K., Derks C., Filippov M. A., Muller U. and De Strooper B. (2006) Regulated intramembrane proteolysis of amyloid precursor protein and regulation of expression of putative target genes. EMBO Rep. 7, 739745.
  • Higashi S. and Miyazaki K. (2003) Novel processing of beta-amyloid precursor protein catalyzed by membrane type 1 matrix metalloproteinase releases a fragment lacking the inhibitor domain against gelatinase A. Biochemistry 42, 65146526.
  • Hiraoka Y., Ohno M., Yoshida K., Okawa K., Tomimoto H., Kita T. and Nishi E. (2007) Enhancement of alpha-secretase cleavage of amyloid precursor protein by a metalloendopeptidase nardilysin. J. Neurochem. 102, 15951605.
  • Hiraoka Y., Yoshida K., Ohno M., Matsuoka T., Kita T. and Nishi E. (2008) Ectodomain shedding of TNF-alpha is enhanced by nardilysin via activation of ADAM proteases. Biochem. Biophys. Res. Commun. 370, 154158.
  • Hoe H. S., Cooper M. J., Burns M. P., Lewis P. A., Van Der Brug M., Chakraborty G., Cartagena C. M., Pak D. T., Cookson M. R. and Rebeck G. W. (2007) The metalloprotease inhibitor TIMP-3 regulates amyloid precursor protein and apolipoprotein E receptor proteolysis. J. Neurosci. 27, 1089510905.
  • Jacobsen K. T. and Iverfeldt K. (2009) Amyloid precursor protein and its homologues: a family of proteolysis-dependent receptors. Cell. Mol. Life Sci. 66, 22992318.
  • Janes P. W., Saha N., Barton W. A., Kolev M. V., Wimmer-Kleikamp S. H., Nievergall E., Blobel C. P., Himanen J. P., Lackmann M. and Nikolov D. B. (2005) Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell 123, 291304.
  • Jorissen E., Prox J., Bernreuther C. et al. (2010) The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex. J. Neurosci. 30, 48334844.
  • Kim M. L., Zhang B., Mills I. P., Milla M. E., Brunden K. R. and Lee V. M. (2008) Effects of TNFalpha-converting enzyme inhibition on amyloid beta production and APP processing in vitro and in vivo. J. Neurosci. 28, 1205212061.
  • Kim M., Suh J., Romano D. et al. (2009) Potential late-onset Alzheimer’s disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity. Hum. Mol. Genet. 18, 39873996.
  • Koike H., Tomioka S., Sorimachi H., Saido T. C., Maruyama K., Okuyama A., Fujisawa-Sehara A., Ohno S., Suzuki K. and Ishiura S. (1999) Membrane-anchored metalloprotease MDC9 has an alpha-secretase activity responsible for processing the amyloid precursor protein. Biochem. J. 343 Pt 2, 371375.
  • Kojro E., Gimpl G., Lammich S., Marz W. and Fahrenholz F. (2001) Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. Proc. Natl Acad. Sci. USA 98, 58155820.
  • Kojro E., Postina R., Buro C., Meiringer C., Gehrig-Burger K. and Fahrenholz F. (2006) The neuropeptide PACAP promotes the alpha-secretase pathway for processing the Alzheimer amyloid precursor protein. FASEB J. 20, 512514.
  • Kojro E., Fuger P., Prinzen C., Kanarek A. M., Rat D., Endres K., Fahrenholz F. and Postina R. (2010) Statins and the squalene synthase inhibitor zaragozic acid stimulate the non-amyloidogenic pathway of amyloid-beta protein precursor processing by suppression of cholesterol synthesis. J. Alzheimers Dis. 20, 12151231.
  • Koo E. H. and Squazzo S. L. (1994) Evidence that production and release of amyloid beta-protein involves the endocytic pathway. J. Biol. Chem. 269, 1738617389.
  • Kuhn P. H., Wang H., Dislich B., Colombo A., Zeitschel U., Ellwart J. W., Kremmer E., Rossner S. and Lichtenthaler S. F. (2010) ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J. 29, 30203032.
  • Lammich S., Kojro E., Postina R., Gilbert S., Pfeiffer R., Jasionowski M., Haass C. and Fahrenholz F. (1999) Constitutive and regulated alpha-secretase cleavage of Alzheimer’s amyloid precursor protein by a disintegrin metalloprotease. Proc. Natl Acad. Sci. USA 96, 39223927.
  • Lammich S., Schobel S., Zimmer A. K., Lichtenthaler S. F. and Haass C. (2004) Expression of the Alzheimer protease BACE1 is suppressed via its 5′-untranslated region. EMBO Rep. 5, 620625.
  • Lammich S., Buell D., Zilow S., Ludwig A. K., Nuscher B., Lichtenthaler S. F., Prinzen C., Fahrenholz F. and Haass C. (2010) Expression of the anti-amyloidogenic secretase ADAM10 is suppressed by its 5′-untranslated region. J. Biol. Chem. 285, 1575315760.
  • Le Gall S. M., Bobe P., Reiss K., Horiuchi K., Niu X. D., Lundell D., Gibb D. R., Conrad D., Saftig P. and Blobel C. P. (2009) ADAMs 10 and 17 represent differentially regulated components of a general shedding machinery for membrane proteins such as transforming growth factor alpha, L-selectin, and tumor necrosis factor alpha. Mol. Biol. Cell 20, 17851794.
  • Lichtenthaler S. F. (2006) Ectodomain shedding of the amyloid precursor protein: cellular control mechanisms and novel modifiers. Neuro-degen. Dis. 3, 262269.
  • Lopez-Perez E., Seidah N. G. and Checler F. (1999) Proprotein convertase activity contributes to the processing of the Alzheimer’s beta-amyloid precursor protein in human cells: evidence for a role of the prohormone convertase PC7 in the constitutive alpha-secretase pathway. J. Neurochem. 73, 20562062.
  • Lopez-Perez E., Zhang Y., Frank S. J., Creemers J., Seidah N. and Checler F. (2001) Constitutive alpha-secretase cleavage of the beta-amyloid precursor protein in the furin-deficient LoVo cell line: involvement of the pro-hormone convertase 7 and the disintegrin metalloprotease ADAM10. J. Neurochem. 76, 15321539.
  • Marcade M., Bourdin J., Loiseau N., Peillon H., Rayer A., Drouin D., Schweighoffer F. and Desire L. (2008) Etazolate, a neuroprotective drug linking GABA(A) receptor pharmacology to amyloid precursor protein processing. J. Neurochem. 106, 392404.
  • Marcello E., Gardoni F., Mauceri D. et al. (2007) Synapse-associated protein-97 mediates alpha-secretase ADAM10 trafficking and promotes its activity. J. Neurosci. 27, 16821691.
  • Marcello E., Gardoni F., Di Luca M. and Perez-Otano I. (2010) An arginine stretch limits ADAM10 exit from the endoplasmic reticulum. J. Biol. Chem. 285, 1037610384.
  • Marcinkiewicz M. and Seidah N. G. (2000) Coordinated expression of beta-amyloid precursor protein and the putative beta-secretase BACE and alpha-secretase ADAM10 in mouse and human brain. J. Neurochem. 75, 21332143.
  • Meziane H., Dodart J. C., Mathis C., Little S., Clemens J., Paul S. M. and Ungerer A. (1998) Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice. Proc. Natl Acad. Sci. USA 95, 1268312688.
  • Naus S., Reipschlager S., Wildeboer D., Lichtenthaler S. F., Mitterreiter S., Guan Z., Moss M. L. and Bartsch J. W. (2006) Identification of candidate substrates for ectodomain shedding by the metalloprotease-disintegrin ADAM8. Biol. Chem. 387, 337346.
  • Nikolaev A., McLaughlin T., O’Leary D. D. and Tessier-Lavigne M. (2009) APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457, 981989.
  • Nishi E., Hiraoka Y., Yoshida K., Okawa K. and Kita T. (2006) Nardilysin enhances ectodomain shedding of heparin-binding epidermal growth factor-like growth factor through activation of tumor necrosis factor-alpha-converting enzyme. J. Biol. Chem. 281, 3116431172.
  • Nitsch R. M., Slack B. E., Wurtman R. J. and Growdon J. H. (1992) Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258, 304307.
  • Nitsch R. M., Deng M., Tennis M., Schoenfeld D. and Growdon J. H. (2000) The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer’s disease. Ann. Neurol. 48, 913918.
  • Nixon R. A. (2005) Endosome function and dysfunction in Alzheimer’s disease and other neurodegenerative diseases. Neurobiol. Aging 26, 373382.
  • O’Connor T., Sadleir K. R., Maus E. et al. (2008) Phosphorylation of the translation initiation factor eIF2alpha increases BACE1 levels and promotes amyloidogenesis. Neuron 60, 9881009.
  • Ohno M., Hiraoka Y., Matsuoka T. et al. (2009) Nardilysin regulates axonal maturation and myelination in the central and peripheral nervous system. Nat. Neurosci. 12, 15061513.
  • Olsson A., Hoglund K., Sjogren M. et al. (2003) Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients. Exp. Neurol. 183, 7480.
  • Parkin E. and Harris B. (2009) A disintegrin and metalloproteinase (ADAM)-mediated ectodomain shedding of ADAM10. J. Neurochem. 108, 14641479.
  • Postina R., Schroeder A., Dewachter I. et al. (2004) A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J. Clin. Invest. 113, 14561464.
  • Prinzen C., Muller U., Endres K., Fahrenholz F. and Postina R. (2005) Genomic structure and functional characterization of the human ADAM10 promoter. FASEB J. 19, 15221524.
  • Prinzen C., Trumbach D., Wurst W., Endres K., Postina R. and Fahrenholz F. (2009) Differential gene expression in ADAM10 and mutant ADAM10 transgenic mice. BMC Genomics 10, 66.
  • Pruessmeyer J. and Ludwig A. (2009) The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer. Semin. Cell Dev. Biol. 20, 164174.
  • Reiss K. and Saftig P. (2009) The “A Disintegrin And Metalloprotease” (ADAM) family of sheddases: physiological and cellular functions. Semin. Cell Dev. Biol. 20, 126137.
  • Reiss K., Maretzky T., Ludwig A., Tousseyn T., De Strooper B., Hartmann D. and Saftig P. (2005) ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and beta-catenin nuclear signalling. EMBO J. 24, 742752.
  • Ring S., Weyer S. W., Kilian S. B. et al. (2007) The secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient to rescue the anatomical, behavioral, and electrophysiological abnormalities of APP-deficient mice. J. Neurosci. 27, 78177826.
  • Roberts S. B., Ripellino J. A., Ingalls K. M., Robakis N. K. and Felsenstein K. M. (1994) Non-amyloidogenic cleavage of the beta-amyloid precursor protein by an integral membrane metalloendopeptidase. J. Biol. Chem. 269, 31113116.
  • Rossner S., Sastre M., Bourne K. and Lichtenthaler S. F. (2006) Transcriptional and translational regulation of BACE1 expression–implications for Alzheimer’s disease. Prog. Neurobiol. 79, 95111.
  • Sennvik K., Fastbom J., Blomberg M., Wahlund L. O., Winblad B. and Benedikz E. (2000) Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer’s disease patients. Neurosci. Lett. 278, 169172.
  • Simons M., Destrooper B., Multhaup G., Tienari P. J., Dotti C. G. and Beyreuther K. (1996) Amyloidogenic processing of the human amyloid precursor protein in primary cultures of rat hippocampal neurons. J. Neurosci. 16, 899908.
  • Sisodia S. S. (1992) Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc. Natl Acad. Sci. USA 89, 60756079.
  • Skovronsky D. M., Moore D. B., Milla M. E., Doms R. W. and Lee V. M. (2000) Protein kinase C-dependent alpha-secretase competes with beta-secretase for cleavage of amyloid-beta precursor protein in the trans-golgi network. J. Biol. Chem. 275, 25682575.
  • Slack B. E., Ma L. K. and Seah C. C. (2001) Constitutive shedding of the amyloid precursor protein ectodomain is up- regulated by tumour necrosis factor-alpha converting enzyme. Biochem. J. 357, 787794.
  • Steiner H., Fluhrer R. and Haass C. (2008) Intramembrane proteolysis by gamma-secretase. J. Biol. Chem. 283, 2962729631.
  • Stein T. D., Anders N. J., DeCarli C., Chan S. L., Mattson M. P. and Johnson J. A. (2004) Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J. Neurosci. 24, 77077717.
  • Talamagas A. A., Efthimiopoulos S., Tsilibary E. C., Figueiredo-Pereira M. E. and Tzinia A. K. (2007) Abeta(1–40)-induced secretion of matrix metalloproteinase-9 results in sAPPalpha release by association with cell surface APP. Neurobiol. Dis. 28, 304315.
  • Tanabe C., Hotoda N., Sasagawa N., Sehara-Fujisawa A., Maruyama K. and Ishiura S. (2007) ADAM19 is tightly associated with constitutive Alzheimer’s disease APP alpha-secretase in A172 cells. Biochem. Biophys. Res. Commun. 352, 111117.
  • Taylor D. R., Parkin E. T., Cocklin S. L., Ault J. R., Ashcroft A. E., Turner A. J. and Hooper N. M. (2009) Role of ADAMs in the ectodomain shedding and conformational conversion of the prion protein. J. Biol. Chem. 284, 2259022600.
  • Van Tetering G., Van Diest P., Verlaan I., Van Der Wall E., Kopan R. and Vooijs M. (2009) The metalloprotease ADAM10 is required for notch1 S2 cleavage. J. Biol. Chem. 284, 3101831027.
  • Tippmann F., Hundt J., Schneider A., Endres K. and Fahrenholz F. (2009) Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin. FASEB J. 23, 16431654.
  • Tousseyn T., Thathiah A., Jorissen E. et al. (2009) ADAM10, the rate-limiting protease of regulated intramembrane proteolysis of Notch and other proteins, is processed by ADAMS-9, ADAMS-15, and the gamma-secretase. J. Biol. Chem. 284, 1173811747.
  • Vaisar T., Kassim S. Y., Gomez I. G., Green P. S., Hargarten S., Gough P. J., Parks W. C., Wilson C. L., Raines E. W. and Heinecke J. W. (2009) MMP-9 sheds the beta2 integrin subunit (CD18) from macrophages. Mol. Cell Proteomics 8, 10441060.
  • Vassar R., Bennett B. D., Babu-Khan S. et al. (1999) Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735741.
  • Wakabayashi T., Craessaerts K., Bammens L. et al. (2009) Analysis of the gamma-secretase interactome and validation of its association with tetraspanin-enriched microdomains. Nat. Cell Biol. 11, 13401346.
  • Weskamp G., Cai H., Brodie T. A., Higashyama S., Manova K., Ludwig T. and Blobel C. P. (2002) Mice lacking the metalloprotease-disintegrin MDC9 (ADAM9) have no evident major abnormalities during development or adult life. Mol. Cell. Biol. 22, 15371544.
  • Xu D., Sharma C. and Hemler M. E. (2009) Tetraspanin12 regulates ADAM10-dependent cleavage of amyloid precursor protein. FASEB J. 23, 36743681.
  • Yin K. J., Cirrito J. R., Yan P. et al. (2006) Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. J. Neurosci. 26, 1093910948.